These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 38740763)
1. Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study. Liu HH; Xie Y; Yang BP; Wen HY; Yang PH; Lu JE; Liu Y; Chen X; Qu MM; Zhang Y; Hong WG; Li YG; Fu J; Wang FS Signal Transduct Target Ther; 2024 May; 9(1):129. PubMed ID: 38740763 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study. Jameie M; Azizmohammad Looha M; Ebadi Z; Amanollahi M; Amani K; Nobahari F; Abdollahi A; Mousavi M; Pourghaz B; Harirchian MH BMC Neurol; 2024 Aug; 24(1):291. PubMed ID: 39164636 [TBL] [Abstract][Full Text] [Related]
3. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594 [No Abstract] [Full Text] [Related]
4. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial. Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial. Zhou H; Zheng H; Peng Y; Su Y; Yu X; Wang W; Li S; Ding Y; Jiao S; Wang Y; Zhu X; Luo L; Dong Z; Liu L; Zhang F; Wu Q; Li J; Zhu F Front Immunol; 2024; 15():1407826. PubMed ID: 38903523 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study. Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial. Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570 [TBL] [Abstract][Full Text] [Related]
10. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583 [TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC; Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults. Hu H; Ma F; Gong L; Wang Y; Xu M; Sun H; Hu Q; Wang P; Han L; Xie H Vaccine; 2024 May; 42(15):3522-3528. PubMed ID: 38704251 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia. Petrović V; Vuković V; Patić A; Marković M; Ristić M PLoS One; 2022; 17(2):e0263468. PubMed ID: 35108321 [TBL] [Abstract][Full Text] [Related]
15. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Wang X; Deng Y; Zhao L; Wang L; Fu Z; Tang L; Ye F; Liu Q; Wang W; Wang S; Hu B; Guan X; Han Z; Tong Y; Rodewald LE; Yin Z; Tan W; Wang F; Huang B Vaccine; 2022 Sep; 40(39):5701-5708. PubMed ID: 36031501 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial. Huang T; Hu Q; Zhou X; Yang H; Xia W; Cao F; Deng M; Teng X; Ding F; Zhong Z; Gao L; Sun J; Gong L BMC Infect Dis; 2024 Apr; 24(1):413. PubMed ID: 38641791 [TBL] [Abstract][Full Text] [Related]
17. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study. Bai S; Zhou S; Zhang J; Chen W; Lv M; Wang J; Zhang A; Wu J; Zhao W Front Immunol; 2024; 15():1437267. PubMed ID: 39229259 [TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]